

## 2024 PRIOR AUTHORIZATION REQUEST FORM

Individual and Family Plans

# Ingrezza

Fax back to: (833) 605-4407 Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, megible, or not attached will delay the review process.			
Patient Name:	Prescriber Name:		
Member Number:	Fax: Phone:		
Date of Birth:	Office Contact:		
Line of Business: □ Exchange - PA	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:		
Primary Phone:	Specialty/facility name	(if applicable):	
☐ REQUEST FOR EXPEDITED REVIEW: By checking the enrollee or the enrollee's ability to regain maximum	this box and signing below, I certify that the standard review im function.	timeframe may seriously jeopardize the life or health of	
Drug Name:			
Strength:  Directions / SIG:			
Directions / Sig.			
Please attach any pertinent medical history including labs and information for this member that may support approval.  Please answer the following questions and sign.			
Q1. Is this a request for continu	uation of therapy with Ingrezza? If YE	S, go to 2. If NO, go to 4.	
☐ Yes	□ No		
•	es the patient have a documented imp th an updated Abnormal Involuntary I	• • •	
☐ Yes	□ No		
	h Huntington's Disease: does the pat toms of Chorea with medical records		
☐ Yes	□ No		
Q4. Is the patient 18 years of a	ge or older?		
☐ Yes	□ No		
Q5. Is Ingrezza being prescribed by or in consultation with a neurologist or psychiatrist?			

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



## 2024 PRIOR AUTHORIZATION REQUEST FORM

Individual and Family Plans

# Ingrezza

Fax back to: (833) 605-4407 Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:	
☐ Yes	□ No	
Q6. Has the patient been diagnosed with tardive dyskinesia and has a copy of the Abnormal Involuntary Movement Scale (AIMS) assessment been attached?		
☐ Yes	□ No	
Q7. Is there documentation that other movement disorders (such as Parkinson's disease, chorea associated with Huntington's disease) have been excluded with documentation attached?		
☐ Yes	□ No	
Q8. Does the patient have documentation of current or former chronic use of a dopamine antagonist (e.g., antipsychotic [first or second generation], metoclopramide, prochlorperazine, droperidol, promethazine)?		
☐ Yes	□ No	
Q9. Does the patient have a diagnosis of Chorea associated with Huntington's Disease with documentation of diagnosis attached?		
☐ Yes	□ No	
Q10. Is there documentation that other movement disorders (such as Tardive Dyskinesia, or Parkinson's disease) have been excluded with documentation attached?		
☐ Yes	□ No	
Q11. For a diagnosis of Chorea associated with Huntington's Disease: is the patient suicidal or do they have a history of untreated or inadequately treated depression?		
☐ Yes	□ No	
Q12. Have all potential contraindications (including congenital long QT syndrome, arrhythmias associated with prolonged QT interval) been excluded?		
☐ Yes	□ No	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



## 2024 PRIOR AUTHORIZATION REQUEST FORM

Individual and Family Plans

# Ingrezza

Fax back to: (833) 605-4407 Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:
Q13. Will Ingrezza be used concurrently with eith strong cytochrome 3A4 (CYP3A4) inducer?	ner a monoamine oxidase (MAO) inhibitor or
☐ Yes	□ No
Q14. Additional Information:	
Prescriber Signature	Date 2024 Prior Authorization Request